Immuneering Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing reports annual results; standalone fourth-quarter financial figures are not provided in the supplied text.
Business context
Immuneering is a clinical-stage oncology company developing oral medicines intended to inhibit the MAPK pathway through “deep cyclic inhibition.” Its lead candidates are IMM-1-104, in a Phase 1/2a trial for advanced RAS-mutant solid tumors, and IMM-6-415, whose IND was cleared in December 2023 for a Phase 1/2a trial in advanced RAS- or RAF-mutant solid tumors. The company has no approved products and generated no product revenue.
Key financial metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0.317 million | Down 100% |
| Research and development | $41.624 million | $36.267 million | Up 14.8% |
| General and administrative | $16.760 million | $15.607 million | Up 7.4% |
| Operating loss | $58.413 million | $51.745 million | Loss widened 12.9% |
| Net loss | $53.472 million | $50.514 million | Loss widened 5.9% |
| Net loss per share | $1.88 | $1.91 | Improved by $0.03 |
| Operating cash used | $48.969 million | $44.101 million | Use increased |
Revenue was historically from computational biology services; the company completed its remaining services and biosample-storage contracts in 2022 and does not anticipate new contracts. With no 2023 revenue, a current gross margin is not meaningful.
At year-end, cash and cash equivalents were $59.406 million and current marketable securities were $26.260 million, totaling approximately $85.7 million in cash, cash equivalents and marketable securities. Total assets were $102.585 million, total liabilities $12.008 million, and stockholders’ equity $90.576 million. Liabilities included $4.463 million of lease obligations; the filing does not report conventional outstanding debt. The company reported no material off-balance-sheet arrangements.
Cash and cash equivalents declined by $13.231 million during 2023. Investing activities provided $7.296 million, primarily from marketable-security maturities net of purchases; financing activities provided $28.441 million, mainly from the April 2023 equity offering. That offering sold 2,727,273 shares at $11.00 per share and generated approximately $28.2 million in net proceeds before offering costs.
Material changes and operating developments
- R&D spending rose as direct costs for IMM-1-104 and IMM-6-415 increased, partly offset by lower spending on earlier-stage and neuroscience programs. IMM-1-104 program costs were $9.289 million; IMM-6-415 costs were $5.171 million.
- Interest income increased to $3.607 million from $1.014 million, reflecting higher interest rates; other income, primarily marketable-security discount accretion, increased to $1.334 million from $0.217 million.
- Class A shares outstanding increased to 29,271,629 at year-end from 26,418,732, largely reflecting the follow-on offering. Stock-based compensation was $5.727 million, compared with $4.064 million.
- Management estimates existing liquidity will fund development and operations into the second half of 2025. This is a forward-looking estimate based on assumptions, and the company states that additional capital will be required to advance development beyond available resources.
Outlook, commentary and principal risks
Management expects losses and R&D, G&A and capital expenditures to continue increasing. It does not expect product sales for several years, if ever, and says future financing may be needed. The filing states there was no substantial doubt about the company’s ability to continue as a going concern for at least 12 months from issuance of the financial statements.
For IMM-1-104, management reported early, limited Phase 1 data: among the small number of patients described, doses up to 320 mg once daily were reported tolerable with no dose-limiting toxicities observed; at 160 mg, reported pERK inhibition exceeded 90%. These interim findings do not establish efficacy or predict later trial results. The company planned to report Phase 1 topline data and dose the first Phase 2a patient in March 2024, with initial data from multiple Phase 2a arms expected in 2024. The FDA granted IMM-1-104 Fast Track designation in February 2024 for pancreatic ductal adenocarcinoma after one prior line of treatment. IMM-6-415’s first patient was expected to be dosed in March 2024.
Key risks include clinical-trial failure, delays or adverse effects; dependence on future financing; uncertain translation of preclinical and early clinical results; reliance on third-party manufacturers, CROs and suppliers; competition; and the need to secure and maintain intellectual-property protection. The company also notes that its market capitalization decline may be an impairment indicator, although no goodwill impairment was recorded in 2023. No material legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements; the auditor did not provide an opinion on internal-control effectiveness.
Important facts for investors to verify
- Subsequent IMM-1-104 and IMM-6-415 trial enrollment, safety, dose selection and data disclosures against the stated 2024 milestones.
- Whether actual cash burn and development spending remain consistent with management’s estimate of runway into the second half of 2025, and the timing and terms of any additional financing.
- Whether preliminary IMM-1-104 findings are confirmed in larger patient cohorts and whether clinical evidence supports the proposed benefit and tolerability claims.
- Progress and scope of IMM-1-104 combination and monotherapy expansion arms, including enrollment plans for pancreatic, melanoma and lung cancer cohorts.
- Patent prosecution and protection for both lead candidates: as of February 15, 2024, the filing reported no issued patents related to the product candidates.
- Lease obligations, particularly the San Diego laboratory lease extending to 2032, and any related facility or cash-flow changes.